We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Diaceutics Plc | LSE:DXRX | London | Ordinary Share | GB00BJQTGV64 | ORD GBP0.002 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 103.00 | 102.00 | 104.00 | 103.00 | 103.00 | 103.00 | 5,041 | 08:00:22 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Testing Laboratories | 19.5M | 724k | 0.0086 | 119.77 | 87.01M |
TIDMDXRX
RNS Number : 9743M
Diaceutics PLC
26 May 2022
26 May 2022
Diaceutics PLC
("Diaceutics" or "the Company")
Results of Annual General Meeting
Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, is pleased to announce that all resolutions proposed at its Annual General Meeting held earlier today, were duly passed by a show of hands.
The proxy votes received from shareholders in respect of each resolution are set out below and are available on the Company's website, www.diaceutics.com .
Resolution For (excluding Against Total Withheld at Chair's discretion) votes cast Number % Number % Number of of votes of votes votes -------------------------------------- -------------- ---------- ---------- ------ ------------ ----------- Ordinary resolution to receive and consider the 2021 Financial 1 Statements 62,700,675 100.00% 0 0.00% 62,700,675 Nil -------------------------------------- -------------- ---------- ---------- ------ ------------ ----------- Ordinary resolution to approve the directors' 2 remuneration report 62,693,325 99.99% 7,350 0.01% 62,700,675 Nil -------------------------------------- -------------- ---------- ---------- ------ ------------ ----------- Ordinary resolution to re-elect Nick Roberts 3 as a director 62,700,675 100.00% 0 0.00% 62,700,675 Nil -------------------------------------- -------------- ---------- ---------- ------ ------------ ----------- Ordinary resolution to re-elect Charles 4 Hindson as a director 61,651,904 98.32% 900,000 1.44% 62,551,904 Nil -------------------------------------- -------------- ---------- ---------- ------ ------------ ----------- Ordinary resolution to re-appoint PricewaterhouseCoopers 5 LLP as auditors 62,550,243 99.75% 1,661 0.01% 62,551,904 Nil -------------------------------------- -------------- ---------- ---------- ------ ------------ ----------- Ordinary resolution to authorise the directors to determine the remuneration 6 of the auditors 62,700,675 100.00% 0 0.00% 62,700,675 Nil -------------------------------------- -------------- ---------- ---------- ------ ------------ ----------- Ordinary resolution to authorise the directors 7 to allot shares 62,699,175 100.00% 0 0.00% 62,700,675 1,500 -------------------------------------- -------------- ---------- ---------- ------ ------------ ----------- Special resolution to authorise the directors to disapply pre-emption 8 rights 62,697,164 99.9% 2,011 0.01% 62,699,175 1,500 -------------------------------------- -------------- ---------- ---------- ------ ------------ ----------- Special resolution to authorise the directors 9 to purchase own shares 60,606,084 99.99% 8,661 0.01% 62,614,745 2,085,930 -------------------------------------- -------------- ---------- ---------- ------ ------------ -----------
Enquiries:
Diaceutics PLC Peter Keeling, Chief Executive Officer Via Alma PR Nick Roberts, Chief Financial Officer Stifel Nicolaus Europe Limited (Nomad & Broker) Tel: +44 (0)20 7710 7600 Ben Maddison, Stewart Wallace, Nick Adams Alma PR Tel: +44(0)20 3405 0205 Caroline Forde, Kieran Breheny, Matthew Young diaceutics@almapr.co.uk
About Diaceutics
At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network(R).
DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
RAGKZGZKFVKGZZM
(END) Dow Jones Newswires
May 26, 2022 10:00 ET (14:00 GMT)
1 Year Diaceutics Chart |
1 Month Diaceutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions